



FRANCE 2030: PHOST'IN THERAPEUTICS IS AWARDED 1.7 MILLION EUROS IN THE I-NOV COMPETITION TO SUPPORT CLINICAL TRIAL AND INDUSTRIALIZATION OF ITS FIRST-IN-CLASS N-GLYCOSYLATION INHIBITOR

Montpellier, France – July 2023, 4th

Phost'in Therapeutics (Montpellier, France), a biotech company focused on the discovery and development of N-glycosylation inhibitors for the treatment of cancer and other serious diseases, is proud to announce being a winner in the 9th wave of the highly competitive i-Nov innovation competition.

The i-Nov Innovation Competition selects and supports innovation projects with particularly strong potential for the French economy. Funded by the French government through via France2030 and hosted by the French public investment bank bpifrance, i-Nov selects this year 53 innovating projects for its 9th wave, for a total cost of 56.3M€.

Phost'in Therapeutics has the ambition to develop breakthrough treatments for patients with aggressive cancers and other serious diseases, and was awarded in the lifescience category for the project "GLYCOPHAST: Clinical Trial and industrialization of PhOx430".

Started in 2022, the clinical trial of the First-In-Class selective GnT-V inhibitor PhOx430 continues at a good pace in France and Italy, with the effects of a selective N-glycosylation inhibition being clinically assessed for a first time. The results will open new solutions for the treatment of solid tumors, in particular for cancers without therapeutic solution. This step must establish Phost'in Therapeutics as an undisputed international leader of glyco-immuno-therapies.

Karine Chorro, CEO of Phost'in Therapeutics, said: *"We are really honoured of this prize. It is for us a great pride to be recognized again by the French Government, after receiving in 2014 the National Prize in the lifescience category of the early-stage I-Lab competition. It demonstrates the hard work and the achievements of Phost'in since this first award, and the importance of the French Government's action to support companies from the research stage to industrialization"*.

About PhOx430

PhOx430 is a First-in-Class N-glycosylation inhibitor, designed to target GnT-V, a key n-glycosylation enzyme responsible for suppressing the immune response and supporting cancer proliferation as well as formation of fibrotic tissues. PhOx430 is currently evaluated in Europe in an adaptive Phase I/II in patients with advanced solid tumors (the PhAST trial). It is also the first program from the Phost'Screen™ platform that combines unique and patented chemical libraries with cutting-edge screening tools to produce selective n-glycosylation inhibitors for the treatment of cancer and other serious immunoinflammatory diseases.

About Phost'in Therapeutics

Phost'in Therapeutics is a biotechnology company specialized in the discovery and development of NCE's specifically targeting abnormal pathogenic glycosylation mechanisms. In addition to PhOx430 clinical development, the company leads upstream research programs in several other diseases using its unique expertise and discovery platform. A spin-off of the academic world, Phost'in possesses, in addition to its own patents, an exclusive license for two families of academic patents owned by CNRS



(Centre National de la Recherche Scientifique), ENSCM (Ecole Nationale Supérieure de Chimie de Montpellier), and the Universities of Montpellier, Sorbonne Paris Nord and Paris Saclay. Based in Montpellier, France, the company was awarded a national Special Prize in the 2014 ILab competition of the French Research Ministry at its creation and has since received the renewed support of bpiFrance, LifeScience cluster Eurobiomed, Region Occitanie and Montpellier Med Vallée. www.phostin.com

About I-nov innovation competition :

https://www.gouvernement.fr/sites/default/files/contenu/piece-jointe/2023/01/recueil_des_laureats_i-nov_vague_9_vf.pdf

Contact:

Karine Chorro, CEO

contact@phostin.com

Phost'in Therapeutics, 104 rue de la Galera, 34 090 Montpellier FRANCE